There was no statistically significant change in the median number of metastases (5.0 vs. 7.5, p = 0.13), the median size of the largest metastasis (12.5 vs. 15.0 mm, p = 0.71), simultaneous lymph node dissections (31% vs. 19%, p = 0.06) or the number of patients with general metastatic disease (stage IV) at the time of ILP treatment (85% vs. 92%, p = 0.25). Here, XIAP is linked to metastatic neoplasm.